跳至主要内容
临床试验/NL-OMON29314
NL-OMON29314招募中不适用

Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0.

AZM0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
AZM
入组人数
66

研究概览

简要总结

Aarnoutse, R., de Vos-Geelen, J. M. P. G. M., Penders, J., Boerma, E. G., Warmerdam, F. A. R. M., Goorts, B., Olde Damink, S. W. M., Soons, Z., Rensen, S. S. M., and Smidt, M. L. (2017) Study protocol on the role of intestinal microbiota in colorectal cancer treatment: a pathway to personalized medicine 2.0, International Journal of Colorectal Disease, 1-8.

研究设计

研究类型
Observational

入排标准

入选标准

  • Patients diagnosed with metastatic and/or irresectable CRC who will be treated with oral capecitabine (with or without intravenous bevacizumab) or oral trifluridine/tipiracil (TAS-102).
  • Aged 18 years or older.

排除标准

  • Proven Microsatellite instability (MSI).
  • Has not received any prior systemic therapy for the treatment of CRC during the previous 4 weeks prior to start of the current line of capecitabine or TAS-102.

研究者

发起方
AZM

相似试验